Gastroenterology

Your daily dose of the clinical news you may have missed.

Restoration of certain bacteria in the gut microbiome may help ameliorate common symptoms associated with long COVID, according to new research.

A 62-year-old woman reports several days of abdominal bloating and vomiting that changed 2 hours ago into severe generalized pain. Review the bedside ultrasound, here.

The novel potassium-competitive acid blocker is the first new treatment approved for the potentially cancer-producing GI disease in 30 years.

Your daily dose of the clinical news you may have missed.

A pivotal phase 3 clinical trial showed Cologuard significantly more likely than FIT to detect cancerous and advanced precancerous lesions.

Dupilumab, a monoclonal antibody targeting type 2 inflammation, would be the first treatment of its kind for younger children with eosinophilic esophagitis.

Patients hospitalized for Clostridioides difficile infection who also were vitamin D-deficient were at higher risk of recurrence—but lower risk of mortality.

A daily dose of clinical news on Patient Care you may have missed.

Postmenopausal women who consumed 1 or more sugary drinks daily had a nearly 2-fold increased risk of liver cancer in a study of more than 98 000.

Constipation, bloating, and abdominal pain worsening over 1 week bring a woman in her mid-70s to the ED. Labs are normal. What do you see on the CT scan?

Your daily dose of clinical news you may have missed.

Your daily dose of clinical news you may have missed.

Findings elaborate on the pathophysiological differences in autoimmunity and atrial fibrillation risk between men and women.

Direct-acting antiviral treatment was independently associated with a lower risk of mortality and liver and nonliver outcomes in a large study of adults with chronic hepatitis C.

The analysis of nearly 300 000 individuals found those with IBD were more likely than the general population to have hypertension and that only UC was independently associated.

Your daily dose of clinical news you may have missed.

In patients with IBS-D, 2 types of acupuncture delivered substantial improvements in abdominal pain score and frequency of loose stool after 4 weeks of treatment.

Findings from a new study suggest that supplementing standard care for obesity with butyrate helped reduce BMI, improve glucose metabolism, and reduce inflammation markers.

The single-dose biotherapeutic remained effective through 6 months for more than 90% of phased 3 clinical trial participants, according to Ferring Pharmaceuticals.

Pooled phase 3 data from LIBERTY-EoE-TREET presented at ACAAI 2022 reinforce May 2022 FDA approval of dupilumab for eosinophilic esophagitis.

Identification of unique IBS subsets has implications for more individualized treatment as well as approaches to clinical trials, say study authors.

Your daily dose of clinical news from Patient Care Online.

Over half of induction responder patients who received ustekinumab at maintenance baseline were in symptomatic remission 4 years later, according to data presented at UEG Week 2022.

The woman is in her mid-fifties, diarrhea has been persistent for 10 days and BUQ pain for 2 days. What does the CT show? What's your diagnosis?